Inicio > Endocrinología y Nutrición > Nuevos avances diagnósticos y terapéuticos en el feocromocitoma > Página 7

Nuevos avances diagnósticos y terapéuticos en el feocromocitoma

Psicológico: ansiedad, ataque de pánico, trastorno somatiforme, hiperventilación, facticio (ej. fármacos, Valsalva)

Farmacológico: Suspensión brusca de inhibidores adrenérgicos, IMAO, drogas (cocaína, LSD…), flush alcohol-clorpropamida, vancomicina (¨síndrome hombre rojo¨)

Neurológico: neuropatía autonómica, síndrome taquicardia ortostática postural (POTS), cefalea migrañosa, epilepsia diencefálica, ictus, insuficiencia cerebrovascular

Otras: mastocitosis, síndrome carcinoide, anafilaxia recurrente idiopática

REFERENCIAS BIBLIOGRÁFICAS

  1. Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant A, Clive S, et al. Benign para-gangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001; 85:5210-6.
  2. Sanchez Turcios RA. Feocromocitoma: diagnóstico y tratamiento. Rev Mex Cardiol. 2010; 21(3):124-137.
  3. Beard CM, Sheps SG, Kurland LT, et al. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1983; 58(12):802-4.
  4. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, et al. A survey on adrenal incidentaloma in Italy. Study group adrenal tumours of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000; 85:637-44.
  5. Guerrero MA, Schreinemakers JM, Vriens MR, et al. Clinical spectrum of pheochromo-cytoma. J Am Coll Surg. 2009; 209(6):727-32.
  6. Kudva YC, Young WF, Thompson GB, et al. Adrenal incidentaloma: An important compo-nent of the clinical presentation spectrum of benign sporadic adrenal pheochromocytoma. The Endocrinologist. 1999; 9:77-80.
  7. Baguet JP, Hammer L, Mazzuco TL, et al. Circumstances of discovery of phaeo-chromocytoma: a restrocpective study of 41 consecutive patients. Eur J Endocrinol. 2004; 150(5):681-6.
  8. Manger WM, Gifford RW. Pheochromocytoma. J Clin Hypertens (Greenwich). 2002; 4(1):62-72.
  9. Bravo EL, Gifford RW Jr. Pheochromocytoma. Endocrinol Metab Clin North Am. 1993; 22(2):329-41.
  10. Kassim TA, Clarke DD, Mai VQ, et al. Catecolamine-induced cardiomyopathy. Endocr Pract. 2008; 14(9):1137-49.
  11. Sibal L, Jovanovic A, Agarwal SC, et al. Phaeochromocytomas presenting as acute crises after beta blockade therapy. Clin Endocrinol (Oxf). 2006; 65(2):186-90.
  12. Stenström G, Sjöström L, Smith U. Diabetes mellitus in phaeochromocytoma. Fasting blood glucose levels bejore and after surgery in 60 patients with phaeochromocytoma. Acta Endocri-nol (Copenh). 1984; 106(4):511-5.
  13. Bravo EL. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheo-chromocytoma. Endocr Rev. 1994; 15(3):356-68.
  14. Pomares FJ, Cañas R, Rodríguez JM, et al. Differences between sporadic and multiple endocrine neoplasia type 2ª phaeochromocytoma. Clin Endocrinol (Oxf). 1998; 48(2):195-200.
  15. Walther MM, Reiter R, Keiser HR, et al. Clinical and genetic characterization of pheochro-mocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol. 1999; 162:659-64.
  16. Walen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol. 1992; 147(1):1-10.
  17. Plouin PF, Chatellier G, Fofol I, Corvol P. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension. 1997; 29(5):1133-9.
  18. Goldstein RE, O´Neill JA Jr, Holcomb GW 3rd, eta al. Clinical experience over 48 years with pheochromocytoma. Ann Surg. 1999; 229(6):755-64.
  19. Brouwers FM, Eisenhofer G, Tao JJ, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006; 91:4505-9.
  20. Manu P, Runge LA. Biochemical screening for pheochromocytoma. Superiority of urinary metanephrines measurements. Am J Epidemiol. 1984; 120:788-90.
  21. Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003; 88(2):553-8.
  22. Lenders JW, Pacak K , Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002; 287(11):1427-34.
  23. De Jong WH, Eisenhofer G, Post WJ, Muskiet FA, de Vries EG, Kema IP. Dietary influen-ces on plasma and urinary metanephrines: implications for diagnosis of catecholamines produ-cing tumours. J Clin Endocrinol Metab. 2009; 94:2841-49.
  24. Deutschbein T, Unger N, Jaeger A, Broecker-Preuss M, Mann K, Petersenn S. Influence of various confounding variables and storage conditions on metanephrine and normetanephrine le-vels in plasma. Clin Endocrinol (Oxf). 2010; 73:153-160.
  25. Eisenhofer G, Lattke P, Herberg M, et al. Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromo-cytoma. Ann Clin Biochem. 2013; 50:62-69.
  26. Cotesta D, Caliumi C, Alò P, et al. High plasma levels of human chromogranin A and adre-nomedullin in patients with pheochromocytoma. Tumori. 2005; 91(1):53-8.
  27. Sjoberg RJ, Simcic KJ, Kidd GS. The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls. Arch Intern Med. 1992; 152(6):1193-7.
  28. Eisenhofer G, Goldstein D, Walther MM, Friberg P, Lenders JWM, Keiser HR, et al. Bio-chemical diagnosis of pheochromocytoma: how to distinguish true from false positive test re-sults. J Clin Endocrinol Metab. 2003; 88:2656-66.
  29. Sawka AM, Prebtani APH, Thabane L, Gafni A, Levine M, Young WF Jr. A systematic re-view of the literature examining the diagnostic efficacy of measurement of fractioned plasma metanephrines in the biochemical diagnosis of pheochromocytoma. BMC Endocr Disord. 2004; 4:2.
  30. Hamrahian AH, Ioachimescu AG, Remer EM, Motta-Ramirez G, Bogabathina H, Levin HS et al. Clinical utility of non-contrast computed tomography attenuation value (Hounsfield units) to differentiate adrenal adenomas/hyperplasias from non-adenomas: Cleveland clinic experien-ce. J Clin Endocrinol Metab. 2005; 90:871-7.
  31. Young WF Jr. Pheochromocytoma. Meet the profesor. The Endocrine Society´s Annual Meeting. 2006:37-42.